...
首页> 外文期刊>Medical oncology >Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients.
【24h】

Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients.

机译:联合化疗治疗的HIV阴性多中心Castleman病患者的临床特征和预后:10例患者的报告。

获取原文
获取原文并翻译 | 示例
           

摘要

To investigate the clinical characteristics and outcome of patients with HIV-negative multicentric Castleman's disease (MCD) treated exclusively with combination chemotherapy, and review literature to improve the diagnosis and management of this disease. A retrospective study was performed on the medical records of 10 patients with HIV-negative MCD treated exclusively with combination chemotherapy at one medical institution from May 2004 to April 2012. And relevant clinical, pathological, radiographic, and laboratory data were examined in order to evaluate treatment responses, with symptom onsets and survival period serving as the endpoints of the assessment. All patients have multifocal lymphadenopathy, and the associated system symptoms are found in 80 % of the cases. All patients were treated with lymphoma-based chemotherapy alone. The duration of follow-up ranged from 5 to 77 months for nine patients. Four patients were treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) alone: One was alive with no evidence of disease, and three were alive with disease. Three patients received cyclophosphamide, vincristine, and prednisone (COP) alone: One remained alive with disease, and two experienced recurrences and passed away. Two had only minimal response to COP and were switched to CHOP, and they were still alive with disease. MCD is a more progressive clinical entity, and long-term follow-up is necessary. CHOP chemotherapy may be an effective treatment option for patients with MCD, whereas when to start chemotherapy, how many cycles of chemotherapy required, and the role of combined radiotherapy remain to be further studied.
机译:目的调查仅接受联合化疗的HIV阴性多中心Castleman病(MCD)患者的临床特征和预后,并复习文献以改善对该病的诊断和治疗。回顾性研究从2004年5月至2012年4月在一家医疗机构对10例仅接受联合化疗的HIV阴性MCD患者的病历进行了回顾。并检查了相关的临床,病理,影像学和实验室数据以评估以症状发作和生存期为评估终点的治疗反应。所有患者均患有多灶性淋巴结病,在80%的病例中发现了相关的系统症状。所有患者仅接受基于淋巴瘤的化疗。 9例患者的随访时间为5至77个月。仅用环磷酰胺,阿霉素,长春新碱和泼尼松(CHOP)治疗了4例患者:1例未发现任何疾病,还活着,而3例则患有疾病。 3例患者仅接受环磷酰胺,长春新碱和泼尼松(COP):1例患者仍然存活,但有2例复发并死亡。其中两个对COP的反应很小,被改用CHOP,他们仍然活着。 MCD是一种更具进展性的临床实体,因此需要长期随访。 CHOP化疗对于MCD患者可能是一种有效的治疗选择,而何时开始化疗,需要化疗的周期数以及联合放疗的作用仍有待进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号